RALEIGH, N.C., Nov. 4, 2010 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) announced that it has successfully completed a Phase I clinical study for DB959, its PPAR (peroxisome proliferator activated receptor) delta/gamma agonist, an oral drug in development for the treatment of Type 2 Diabetes. This study’s main objectives were to determine the safety and pharmacokinetics of single ascending oral doses of DB959Na. Overall, the safety of DB959Na was comparable to placebo with no reports of moderate, severe, or serious adverse events in any subjects in the study. Results of pharmacokinetic measurements indicate that the compound is likely to meet the target dosing regimen of once a day, thus meeting an important goal for the program.
